# OnCo record roar (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/roar/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "roar", "NCT02034110" ;
  schema:name "ROAR (Rare Oncology Agnostic Research) basket: BRAF V600E biliary tract cancer cohort"@en ;
  schema:alternateName "ROAR"@en ;
  schema:description "In the ROAR basket trial, the BRAF-blocking pair dabrafenib and trametinib shrank tumours in about half of 43 people with bile duct or gallbladder cancer carrying the BRAF V600E mutation, which is found in roughly 5 percent of biliary cancers. The pair is approved for any solid tumour with this mutation in the United States and is listed by guidelines for biliary cancer."@en ;
  schema:url <https://onco.cc/trials/roar/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02034110>, <https://doi.org/10.1016/S1470-2045(20)30321-1> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/biliary-tract-cancer/>, <https://onco.cc/terms/rare-cancers/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/braf/> ;
  onco:drugs <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:terms <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/basket-umbrella-platform/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-roar-lancet-oncol-2020/>, <https://onco.cc/key-papers/paper-roar-ann-oncol-2022-update/> .